Raymond James Upgrades Medexus Pharmaceuticals (TSE:MDP) to Outperform

Raymond James upgraded shares of Medexus Pharmaceuticals (TSE:MDP) from a market perform rating to an outperform rating in a report issued on Wednesday morning, Marketbeat reports. Raymond James currently has C$4.00 target price on the stock, up from their previous target price of C$3.00. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at $0.14 EPS, Q1 2026 earnings at $0.22 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.24 EPS, Q4 2026 earnings at $0.24 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $0.90 EPS, FY2028 earnings at $0.89 EPS and FY2029 earnings at $0.89 EPS.

MDP has been the subject of several other reports. Stifel Nicolaus increased their price target on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Leede Financial set a C$8.25 target price on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research note on Monday, September 30th. Finally, Stifel Canada upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, August 12th. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of C$5.25.

Medexus Pharmaceuticals Trading Up 15.0 %

Medexus Pharmaceuticals stock opened at C$2.45 on Wednesday. The stock has a 50 day moving average of C$2.45 and a two-hundred day moving average of C$2.19. Medexus Pharmaceuticals has a twelve month low of C$1.44 and a twelve month high of C$3.16. The stock has a market capitalization of C$60.10 million, a price-to-earnings ratio of 49.00 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.